Article
The "Asian Paradox" in multiple primary lung cancer: a geographic monopole driven by phenotypic divergence.
NPJ primary care respiratory medicine - 6 Apr 2026
Shi Jianwei, Gao Yushun
Abstract excerpt
The global clinical trial landscape for multiple primary lung cancer (MPLC) exhibits a striking geographic anomaly. Through a systematic analysis of 8212 lung cancer registrations (2015-2024), we identified a cohort of 17 trials explicitly targeting MPLC. Analysis revealed an absolute geographic monopole: 100% of these trials were investigator-initiated in China, with a complete absence of active protocols in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
